Harrow, Inc. (NASDAQ:HROW)
| Market Cap | $1.14B-22.0% |
| Revenue (ttm) | $303.25M+21.3% |
| Net Income | -$28.49M-471.2% |
| EPS | -$0.77-400.7% |
| Shares Out | 37.53M |
| PE Ratio | n/a |
| Forward PE | 20.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 911,784 |
| Open | $31.95 |
| Previous Close | $32.13 |
| Day's Range | $30.31 - $32.43 |
| 52-Week Range | $25.76 - $54.85 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | $45.00(+47.98%) |
| Earnings Date | Mar 1, 2027 |
About HROW
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating HROW in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 1, 2027Earnings report
$HROW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in HROW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HROW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HROW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
HROW Revenue by Segment
| Branded | $83.46M | 45.67% |
| VEVYE | $39.70M | 21.72% |
| IHEEZO | $25.30M | 13.84% |
| Compounding | $15.84M | 8.66% |
| TRIESENCE | $10.71M | 5.86% |
| Other branded products | $7.59M | 4.16% |
| Other revenues | $164.00K | 0.09% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New HROW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HROW from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in HROW
| IWMiShares Russell 2000 ETF | $26.36M |
| VTIVanguard Morningstar Total Stock Market ETF | $22.29M |
| FESMFidelity Enhanced Small Cap ETF | $12.03M |
| VXFVanguard Extended Market ETF | $10.29M |
| IWOiShares Russell 2000 Growth ETF | $9.73M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $9.21M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from HROW’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 record revenue and net income growth offset by earnings miss versus estimates; stock rose after hours on results.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.50% |
| BCSM | Baron ETF Trust - Baron SMID Cap ETF | 1.17% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.52% |
| XHYH | BondBloxx USD High Yield Bond Healthcare Sector ETF | 0.26% |
| IWC | iShares Micro-Cap ETF | 0.23% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.22% |
| PQSG | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | 0.21% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.19% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.13% |
| PSC | Principal U.S. Small-Cap Multi-Factor ETF | 0.11% |
| QSML | WisdomTree U.S. SmallCap Quality Growth Fund | 0.10% |
| ACSG | American Century Small Cap Growth Insights ETF | 0.09% |
Weight is the stock’s share of each fund’s holdings.
